MIRA INFORM REPORT

 

 

Report No. :

345912

Report Date :

27.10.2015

 

IDENTIFICATION DETAILS

 

Name :

MULTILAB INDÚSTRIA E COMÉRCIO DE PRODUTOS FARMACÊUTICOS LTDA

 

 

Registered Office :

Rodovia Rs 401, Km 30,1009 - São Jerônimo 96700-000 - São Jerônimo/Rs

 

 

Country :

Brazil

 

 

Date of Incorporation :

01.08.1988

 

 

Legal Form :

Limited Liability Company

 

 

Line of Business :

Manufacture and Trade of Medicines

 

 

No. of Employee :

Not Available

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

No complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Brazil

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 


 

BRAZIL - ECONOMIC OVERVIEW

 

Characterized by large and well-developed agricultural, mining, manufacturing, and service sectors, and a rapidly expanding middle class, Brazil's economy outweighs that of all other South American countries, and Brazil is expanding its presence in world markets. Since 2003, Brazil has steadily improved its macroeconomic stability, building up foreign reserves, and reducing its debt profile by shifting its debt burden toward real denominated and domestically held instruments. Since 2008, Brazil became a net external creditor and all three of the major ratings agencies awarded investment grade status to its debt. After strong growth in 2007 and 2008, the onset of the global financial crisis hit Brazil in 2008. Brazil experienced two quarters of recession, as global demand for Brazil's commodity-based exports dwindled and external credit dried up. However, Brazil was one of the first emerging markets to begin a recovery. In 2010, consumer and investor confidence revived and GDP growth reached 7.5%, the highest growth rate in the past 25 years. After reaching historic lows of 4.5% in early 2014, the unemployment rate remains low, but is rising. Brazil's traditionally high level of income inequality has declined for each of the last 15 years. GDP growth has slowed since 2011, due to several factors, including: overdependence on exports of raw commodities, low productivity, high operational costs, persistently high inflation, and low levels of investment. Brazil's fiscal and current account balances have eroded during the past four years as the government attempted to boost economic growth through targeted tax cuts for industry and incentives to spur household consumption. After winning reelection in October 2014 by a historically narrow margin, President Dilma ROUSSEFF appointed a new economic team led by Finance Minister Joaquim LEVY, who introduced a fiscal austerity package intended to restore the primary account surplus to 1.2% of GDP and preserve the country's investment-grade sovereign credit rating. Brazil seeks to strengthen its workforce and its economy over the long run by imposing local content and technology transfer requirements on foreign businesses, by investing in education through social programs such as Bolsa Familia and the Brazil Science Mobility Program, and by investing in research in the areas of space, nanotechnology, healthcare, and energy.

 

Source : CIA

 

 

Company name and address

 

MULTILAB INDÚSTRIA E COMÉRCIO DE PRODUTOS FARMACÊUTICOS LTDA

 

 

ADDRESSES

 

MAIN ADDRESS:

RODOVIA RS 401, KM 30,1009 - SÃO JERÔNIMO

ZIP CODE/CITY:

96700-000 - SÃO JERÔNIMO/RS

 

 

PHONE:

51 3055-9000

FAX:

51 3055-9000

E-MAIL:

rodrigo.espim@takeda.com

WEB SITE:

www.multilab.com.br

 

BRANCHES:

 

 

 

ADDRESS:

RUA MARIANO DE MATOS,742

ZIP CODE/CITY:

90880-250 PORTO ALEGRE/RS

 

 

ADDRESS:

AV. INSUTRIAL BELGRAF,250 CENTRO

ZIP CODE/CITY:

92990-000 ELDORADO SUL SUL/RS

PHONE:

51 3230-4043

 

 

LEGAL DATA

 

MAIN ACTIVITIES:

 

MANUFACTURE AND TRADE OF MEDICINES.

 

LEGAL FORM:

LIMITED LIABILITY COMPANY

 

 

INCORPORATION DATE:

01/08/1988

REGISTER DATE:

04/08/1988

BALANCE SHEET FILING DATE:

31/12

TAX CONTRIBUTOR NUMBER(CNPJ):

92.265.552/0001-40

STATE REGISTER:

121/0050568

 

 

SHARE CAPITAL:

R$ 527.545.742,00

 

BOARD OF DIRECTORS:

 

 

 

RICARDO WERNER MAREK

MANAGER

EDUARDO JOSE MARTINS

MANAGER

 

 

AUTHORIZED USE OF SIGNATURE

 

THE MANAGERS ARE AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY.

 

SHAREHOLDERS / PARTNERS:

 

 

 

TAKEDA PHARMA AS

99,99%

TAKEDA EUROPE HOLDINGS B V

00,01%

 

AFFILIATES / SUBSIDIARIES:

 

A SCAN THROUGH OUTSIDE SOURCES SHOWED THE SUBJECT AND/OR PARTNERS HAS/HAVE THE FOLLOWING UNCONFIRMED HOLDINGS:

 

TAKEDA GROUP

 

 

 

COMPANY'S BACKGROUND

 

THE SUBJECT WAS ESTABLISHED ON AUGUST 01, 1988 TO BE ENGAGED IN THE SAID LINE OF BUSINESS AND UP TO DATE IT IS STILL OPERATING WITHIN THE GENERAL SCENE REPORTED HEREIN.

 

TRADE NAME: "MULTILAB".

 

CONTACTS WERE MADE THROUGH THE RELATED PARTY TAKEDA DISTRIBUIDORA LTDA LOCALIZADA NO SITUATED AT AV. PORTUGUAL, 1100, RUA MODULO A 8, ITAPEVI - SP CEP 06696-060, TAXPAYER NUMBER CNPJ 11.635.171/0001-03, TELEPHONE 11 5188-4400.

 

REMARKS:

 

ACCORDING TO AMENDMENT TO THE ARTICLES OF INCORPORATION DATED OF JULY 02, 2012 (AND PURCHASE AND SALE OF SHARES CONTRACT DATED OF MAY 25, 2012) THE PARTNERS GENÉSIO CERVO AND TERESINHA GOBBI, WITHDREW FROM THE PARTNERSHIP AND TRANSFERRED THE TOTALITY OF SHARES TO TAKEDA FARMACÊUTICA BRASIL LTDA., WHICH BELONGS TO THE TAKEDA GROUP FROM JAPAN. OUTSIDE SOURCES STATED THAT ACQUISITION AMOUNTED TO R$ 540 MILLIONS. FURTHER, IN 2011 THE TAKEDA GROUP ALSO ACQUIRED NYCOMED FROM SWITZERLAND FOR THE AMOUNT OF 14 BILLION.

 

FURTHER, WE HAVE BEEN INFORMED THAT SUBJECT HAS TAKEN OVER ITS CONTROLLER TAKEDA FARMACÊUTICA BRASIL LTDA. HOWEVER, WHEN CONSULTING THE STATE OF RIO GRANDE DO SUL REGISTER OF COMPANIES TAKEDA FARMACÊUTICA BRASIL LTDA. STILL APPEARS AS THE COMPANY'S CONTROLLER. THE SUBJECT MUST FILE AN AMENDMENT TO THE REGISTER OF COMPANIES INFORMING THAT THE TAKEOVER HAS OCCURRED AND APPOINT THE NEW PARTNERSHIP COMPOSITION. IN THE MEANTIME WE WILL BE INFORMING THE COMPANY'S PARTNER ACCORDING TO THE REGISTER OF COMPANIES.

 

REMARKS:

--------

 

WHEN CONTACTING THE SUBJECT WE INTERVIEWED MR. RODRIGO ESPIM - FINANCIAL DEPARTMENT, WHO INFORMED THAT WOULD NOT DISCLOSE ANY KIND OF INFORMATION UNLESS THE INQUIRING PARTY'S NAME WAS DISCLOSED.

 

IF IT IS POSSIBLE TO DISCLOSE THE NAME OF THE INTERESTED SUPPLIER OF THE SUBJECT, WE MAY RESUME OUR CONTACTS AND TRY TO OBTAIN FURTHER INFORMATION.

 

THE DATA CONTAINED HEREIN WERE OBTAINED FROM OUTSIDE SOURCES, OUR DATABASE AND OFFICIAL. NO FURTHER DATA WAS AVAILABLE WITH SEVERAL SOURCES USUALLY INVESTIGATED.

 

PUBLIC INFORMATION:

 

PROTESTS:

 

5  PROTESTS,TOTAL AMOUNT R$ 43.855,38

 

DETAILS OF LATEST PROTESTS:

 

NOTARY OFFICE:

DATE:

VALUE:

1º CARTÓRIO DE SÃO JERÔNIMO-RS

06/10/2015

R$ 16.430,00

1º CARTÓRIO DE SÃO JERÔNIMO-RS

14/10/2015

R$ 1.143,00

1º CARTÓRIO DE SÃO JERÔNIMO-RS

02/10/2015

R$ 394,00

1º CARTÓRIO DE SÃO JERÔNIMO-RS

02/10/2015

R$ 142,04

1º CARTÓRIO DE SÃO JERÔNIMO-RS

02/10/2015

R$ 25.746,34

 

 

FINANCIAL INFORMATION

 

DUE TO THE SUBJECT'S LEGAL FORM, IT IS NOT OBLIGED TO PUBLISH THE BALANCE SHEET INFORMATION. WHEN INTERVIEWING SOURCES AT THE SUBJECT COMPANY DECLINED TO PROVIDE ANY KIND OF FINANCIAL INFORMATION.

 

OUR INVESTIGATION THROUGH THE OUTSIDE SOURCES SHOWED NO FINANCIAL DATA ABOUT THE SUBJECT.

 

EXCHANGE RATE:

 

 

US$ 1,00 = R$ 3,93

 - OFFICIAL RATE ON 21/10/2015

 

COMMENTS ON THE FINANCIAL INFORMATION:

 

IN THE ABSENCE OF FINANCIAL INFORMATION NO COMMENTS CAN BE MADE ABOUT THE SUBJECT'S CURRENT FINANCIAL STANDING.

 

REAL ESTATE:

 

OWNED PREMISES ARE VALUED AT R$ 14.547.933,64

 

VEHICLES:

 

OWNED VEHICLES ARE VALUED AT R$ 79.452,47

 

MACHINES:

 

OWNED MACHINES AND EQUIPMENTS ARE VALUED AT R$ 12.527.895,24

 

 

INSURANCE

 

THE COMPANY CONTRACTS INSURANCE OVER ITS OPERATIONAL ASSETS IN AMOUNTS CONSIDERED ADEQUATE BY ITS MANAGEMENT

 

 

BANKING REFERENCES

 

 

BRANCH/PHONE:

 

BANCO DO BRASIL S/A

3418-5  /  51 3214-7676

 

BANCO BANRISUL S/A

047  /  51 3223-1799

 

BANCO SAFRA S/A

51 2131-3746

 

 

REMARKS: IN BRAZIL THE BANKS ARE PROHIBITED BY LAW TO PROVIDE INFORMATION OR ANY KIND OF COMMENTS ABOUT THEIR CLIENTS. DUE TO THIS LAW PROHIBITION WE ARE UNABLE TO PROVIDE ANY BANKING DETAILS.

 

ACCORDING TO THE CENTRAL BANK OF BRAZIL OFFICIAL REPORT, THE COMPANY HAS NO RETURNED CHECKS UP TO DATE. (IN THE TERMS OF "CIRCULAR 1682 BRAZILIAN CENTRAL BANK").

 

 

ACTIVITIES COMMENTS

 

SUBJECT IS ENGAGED IN THE MANUFACTURE AND TRADE OF MEDICINES.

 

IMPORT AND EXPORT:

 

   IMPORTS FROM:

ITALY, GERMANY, MEXICO, CANADA AND INDIA.

 

   EXPORTS TO:

DOES NOT EXPORT.

 

MAIN CLIENTS:

 

 

 

 

 

DOMESTIC CLIENTS:

 

PHONE:

CERVOSUL DISTRIB MEDICAMENTOS LTDA

 

51 3230-4000

DISTRIBUIDORA BRINGEL LTDA

 

92 2126-4000

DIVAMED DISTR IRMÃOS VALOTTO MEDIC

 

14 3405-5500

EMEFARMA RIO REPRESENTAÇÕES LTDA

 

21 2187-8900

GALINDO DIT E REPRES LTDA (PE)

 

81 3343-8999

GAUCH FARMA MEDICAMENTOS LTDA

 

51 3382-2200

GERRAFARMA DISTR E REPRES LTDA

 

86 3221-2359

GLOBO FARMA DISTRIBUIDORA LTDA

 

75 3603-7800

MS FARMA COMERCIAL LTDA

 

75 3224-0228

NORTEFARMA COMÉRCIO LTDA

 

84 3661-2393

PRODIET FARMACEUTICA S/A

 

41 2169-4848

TAPAJOS DISTR DE PROD FARMAC LTDA

 

92 2123-4000

TOTAL COMERCIO E REPRESENTAÇÕES LTDA

 

85 3311-2350

 

STAFF:

 

   NOT AVAILABLE

 

 

CONCEPT AND FULFILMENT

 

THE SUBJECT IS A WELL-ESTABLISHED COMPANY, OPERATING SINCE 1988. SO FAR IT HAS A CLEAR TRADE HISTORY AND NO PAYMENT PROBLEMS ARE NOTED.

 

THE COMPANY HAS TRADE RELATIONS WITH SEVERAL SUPPLIERS IN BRAZIL. THE SUPPLIERS EXTEND CREDIT FACILITIES TO THE SUBJECT IN TERMS AND AMOUNTS ACCORDING TO THE COMPANY'S NEEDS AND SO FAR NO PAYMENT PROBLEMS ARE NOTED.

 

THE PROTESTS FOUND ARE NOT RELEVANT.

 

MAIN SUPPLIERS:

 

 

 

 

 

DOMESTIC SUPPLIERS:

 

PHONE:

AB FARM QUIMICA LTDA

 

62 3316-3420

BRASKAP COMERCIO E INDÚSTRIA S/A

 

15 3225-3355

CASA DA QUIMICA

 

11 4043-2855

COLORCON DO BRASIL LTDA

 

11 4617-8669

COMERCIAL REBESCHINI DE ÁLCOOL

 

51 3336-1809

FARMAPLAST IND EMBALAGENS PLÁSTICAS

 

11 4612-2700

GENIX INDUSTRIA FARMACEUTICA LTDA

 

11 2067-5600

GRAFICA LOTICOMART LTDA

 

51 3041-3434

IPIRANGA QUIMICA DIVISÃO EMCA

 

11 3245-4416

M CASSAB COM IND LTDA

 

11 2162-7609

NILCATEX TEXTIL LTDA.

 

47 3231-2500

NORTIS FRMACÊUTICA LTDA

 

43 3443-2244

TROMBINI INDUSTRIAL S/A

 

51 2129-2300

VALDEQUIMICA PRODUTOS QUIMICOS

 

11 3721-1077

VEDAT TAMPAS

 

51 3217-1177

WHEATON DO BRASIL INDÚSTRIA COMÉRCIO

 

51 3217-1177

 

FOREIGN SUPPLIERS:

COUNTRY:

 

FERSINSA GB

MEXICO

 

LA FIDUCIARIA

ITALY

 

LEE PHARMA

INDIA

 

 

PAYMENT HISTORY:

 

06 SUPPLIERS REPORTED PAYMENTS:

   TOTAL AMOUNT:  R$ 167.832,00

 

AMOUNT OF INVOICES PAID: 15

TOTAL OF PROMPT PAYMENTS: 98,3%

TOTAL OF DELAYED PAYMENTS: 1,7%

 

HIGHEST INVOICE: R$ 62.078,00

HIGHEST CREDIT: R$ 62.078,00

 

OUTSTANDING INVOICES DUE WITHIN THE NEXT 30 DAYS:

 

---------------------------

SUPPLIERS:

INVOICES:

TOTAL AMOUNT:

DUE WITHIN 30 DAYS

2

2

R$ 10.785,60

 

 

FINAL OPINION

 

BASED ON THE OVERALL DATA AVAILABLE THE SUBJECT MAY BE CONSIDERED FOR NORMAL BUSINESS COMMITMENTS. CREDIT FACILITIES HOWEVER SHOULD BE GRANTED ON FULLY SECURED TERMS ONLY DUE TO THE ABSENCE OF FINANCIAL DATA.

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.64.96

UK Pound

1

Rs.99.54

Euro

1

Rs.71.64

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

SDA

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.